Dae Gon Ha
Stock Analyst at Stifel
(2.60)
# 2,276
Out of 5,056 analysts
46
Total ratings
36.84%
Success rate
7.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Reinstates: Buy | $89 | $71.32 | +24.79% | 4 | Aug 11, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $4.17 | +379.62% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.66 | +12.78% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $48.70 | +51.95% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $8.15 | -63.19% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $10.18 | +528.68% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $203.00 | +8.37% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $33.25 | +281.95% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.26 | +1,372.39% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.92 | +359.18% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.97 | +620.91% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $99.86 | -74.96% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $9.32 | +71.67% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $11.95 | +2,284.94% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.16 | +825.93% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.42 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $19.51 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.23 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.65 | +627.27% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $13.34 | +3,573.16% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Aug 11, 2025
Reinstates: Buy
Price Target: $89
Current: $71.32
Upside: +24.79%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $4.17
Upside: +379.62%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.66
Upside: +12.78%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $48.70
Upside: +51.95%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $8.15
Upside: -63.19%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $10.18
Upside: +528.68%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $203.00
Upside: +8.37%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $33.25
Upside: +281.95%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.26
Upside: +1,372.39%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.92
Upside: +359.18%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.97
Upside: +620.91%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $99.86
Upside: -74.96%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $9.32
Upside: +71.67%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $11.95
Upside: +2,284.94%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.16
Upside: +825.93%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.42
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $19.51
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.23
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.65
Upside: +627.27%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $13.34
Upside: +3,573.16%